Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Will Take Its HGS Bid Hostile; Will Shareholders Buy In?

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK plans to take its $13 per share offer straight to Human Genome Sciences shareholders after being turned down by the company last month.

You may also be interested in...

GSK And HGS Face Off Over Buyout

Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.

GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making

GlaxoSmithKline swoops in to acquire its research partner Human Genome Sciences – made vulnerable by the weak launch of Benlysta – for $13 per share in cash, or about $2.6 billion.

HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta

In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts